BIO-CONVERT A/S

CVR 39842319 · Public limited company (A/S) · Active · High risk

BIO-CONVERT A/S is a Public limited company (A/S), founded on , based in Søborg. The company is registered in the industry fremstilling af farmaceutiske præparater. Our model estimates a bankruptcy risk of 2.8% over the next 12 months, which is 2.0 times the average for Danish companies. 7 annual reports have been published, of which 4 more than six months after the end of the financial year. The latest annual report (31 Mar 2026) shows equity of DKK 2.6m and a net result of DKK -588k. CEO: Allan Traugott Wehnert.

Bankruptcy risk for BIO-CONVERT A/S

2.8%
probability of bankruptcy within 12 months
High risk

2.0 × the average (1.41%) · higher risk than 87% of active Danish companies

Lowest riskHighest risk

Increases the risk

Moves in the last 2 years2 · bankruptcy rate 23.9%2.7×
Share of late annual reports50%–75% · bankruptcy rate 18.4%2.1×
Time at current address0.5–1 yrs · bankruptcy rate 16.5%1.9×
CEO's previous bankruptcies1 · bankruptcy rate 14.2%1.6×
Website registeredYes · bankruptcy rate 12.0%1.4×
RegionHovedstaden · bankruptcy rate 11.6%1.3×
Other companies at the same address100+ · bankruptcy rate 11.5%1.3×
Time since new CEO2–5 yrs · bankruptcy rate 10.8%1.2×

Reduces the risk

CEOs in total (historical)5+ · bankruptcy rate 3.8%0.43×
Company typeA/S · bankruptcy rate 4.4%0.50×
Number of auditors (historical)2 · bankruptcy rate 4.6%0.52×
Auditor registered in CVRYes · bankruptcy rate 4.8%0.55×
Audit opted outNo · bankruptcy rate 4.8%0.55×
Negative equityNo · bankruptcy rate 5.1%0.58×
Reporting classReporting class B · bankruptcy rate 5.7%0.65×
Auditor's statementAudit · bankruptcy rate 5.8%0.66×

The factors show how often companies with the same characteristic went bankrupt compared with the average (“lift”). The risk is a statistical estimate from a model trained on 141,000+ Danish bankruptcies (AUC 0.93) – not a credit rating. Read about the method.

Company details

CVR number
39842319
Status
Active
Company type
Public limited company (A/S)
Founded
(8 years)
Address
Vandtårnsvej 62A, 1. b
2860 Søborg
Municipality
Gladsaxe
Industry
Fremstilling af farmaceutiske præparater (212000)
Bankruptcies in the industry: Fremstilling af farmaceutiske præparater
Share capital
DKK 596k
Auditor
CROWE STATSAUTORISERET REVISIONSINTERESSENTSKAB
Audit opted out
No

Warning signs

Annual reports filed late4 of 7
Missing annual reportNo
Negative equityNo
Equity ratio37.0%
Current ratio9%
Moves (last 2 years)2
CEO changes in total9
CEO's previous bankruptcies1
Other companies at the address119
Going-concern uncertaintyNo

Financials and key figures

Financial year2026202520242023
Gross profitDKK -622kDKK -93kDKK -619kDKK -19k
Net profitDKK -588kDKK -99kDKK -635kDKK -19k
EquityDKK 2.6mDKK 1.4mDKK 1.5mDKK 319k
Total assetsDKK 7.0mDKK 3.5mDKK 2.1mDKK 450k
CashDKK 7,059DKK 55kDKK 153k–
Short-term debtDKK 4.4mDKK 2.1mDKK 647k–
Avg. employees000–

Latest annual report: Reporting class B · auditor's statement: Revisionspåtegning · Crowe.

Filed annual reports

Reporting periodPublishedDays after period end
1 Apr 2025 – 31 Mar 2026184 Late
1 Jan 2024 – 31 Dec 2024183
1 Jan 2023 – 31 Dec 2023184 Late
1 Jan 2022 – 31 Dec 2022178
1 Jan 2021 – 31 Dec 2021179
1 Jan 2020 – 31 Dec 2020195 Late
24 Aug 2018 – 31 Dec 2019259 Late

The annual report must reach the Danish Business Authority no later than 5 months after the end of the financial year. We mark reports published more than 6 months after as “late”.

Management, owners and auditor

RoleNameFromTo
CEOAllan Traugott WehnertCurrent
CEOChristian Torben Hill-Madsen
CEONelli Carla Gotfredsen
CEOChristian Torben Hill-Madsen
CEOTom Glæsner Larsen
CEOChristian Torben Hill-Madsen
CEOHenrik Rouf
BoardPeter Severin BachCurrent
BoardHenrik RoufCurrent
BoardChristian Torben Hill-MadsenCurrent
BoardChristian Torben Hill-Madsen
BoardSamia Sofie Kappe
BoardAllan Traugott Wehnert
BoardHenrik Keller
Owner (100%)Nordicus Partners CorporationCurrent
Owner (100%)Christian Torben Hill-Madsen
Owner (100%)Andreas Hill-Madsen
Owner (100%)Christian Torben Hill-Madsen
Owner (100%)ABCHill Holding ApS
Owner (100%)Alteral Therapeutics ApS
Owner (50%)GK PARTNERS ApS
Owner (33%)Alteral Therapeutics ApS
Owner (25%)GK PARTNERS ApS
Owner (20%)GK PARTNERS ApS
Owner (10%)GK PARTNERS ApS
Owner (25%)AC Nordic ApS
Owner (5%)GK PARTNERS ApS
Owner (5%)ABCHill Holding ApS
AuditorCROWE STATSAUTORISERET REVISIONSINTERESSENTSKABCurrent
AuditorBeierholm Godkendt Revisionspartnerselskab
FounderChristian Torben Hill-MadsenCurrent

The CEOs' other companies

Allan Traugott Wehnert – 7 other companies, of which 1 bankrupt

Christian Torben Hill-Madsen – 14 other companies, of which 2 bankrupt

Nelli Carla Gotfredsen – 1 other companies

Tom Glæsner Larsen – 53 other companies, of which 15 bankrupt

Henrik Rouf – 2 other companies

Address history (3 moves)

Vandtårnsvej 62A, 1. b, 2860 Søborg
Vandtårnsvej 62A, 1. e, 2860 Søborg
Dyrehavevej 3, st., 2930 Klampenborg
Mesterlodden 3A, 1., 2820 Gentofte

Former names

BIO-CONVERT A/S – now
BIO-CONVERT ApS –
Nordicare Danmark ApS –
Life Science Power House ApS –

Other companies at the same address

Similar companies in Gladsaxe

Questions and answers about BIO-CONVERT A/S

Has BIO-CONVERT A/S gone bankrupt?

No, BIO-CONVERT A/S is not registered as bankrupt in the CVR register. Its status is: active.

What is the bankruptcy risk of BIO-CONVERT A/S?

Our model estimates a bankruptcy risk of 2.8% over the next 12 months (high risk), which is 2.0 times the average for Danish companies.

Who is the CEO of BIO-CONVERT A/S?

Allan Traugott Wehnert is the CEO of BIO-CONVERT A/S.

Who is the auditor of BIO-CONVERT A/S?

BIO-CONVERT A/S most recently used CROWE STATSAUTORISERET REVISIONSINTERESSENTSKAB.

When was BIO-CONVERT A/S founded?

BIO-CONVERT A/S was founded on 24 August 2018.

What is the equity of BIO-CONVERT A/S?

Equity was DKK 2.6m according to the annual report for the period ending 31 March 2026.

Source: the CVR register and annual reports published by the Danish Business Authority. The information is updated continuously.